In an associated study focussed on the biomarker supported differential diagnosis of AD, PD, PDD, and DLB, CSF Aβ1-42, total-tau, and phospho-tau were measured in the CSF of a total of 80 patients. This evidence concerns the gene MAPT and Lewy body dementia.